Nutritional Challenges of Incretin-Based Obesity Management Medications: Implications for Clinical Practice

Sep 20, 2025Advances in nutrition (Bethesda, Md.)

Nutritional Issues with Incretin-Based Medications for Obesity and What They Mean for Treatment

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Incretin-based obesity management medications (OMMs) may lead to significant weight loss but also present potential nutritional challenges.

Weight reduction effects from incretin-based OMMs are accompanied by gastrointestinal disturbances and possible loss of lean body mass.
Nutritional challenges could reduce energy expenditure and increase risks of rebound weight gain, sarcopenia, and frailty.
These medications can suppress energy intake but may negatively impact diet quality and macronutrient distribution.
There is a potential risk of vitamin and mineral deficiencies and disordered eating behaviors associated with OMMs.
Specific dietary and behavioral strategies, like higher protein intake and resistance training, may help counteract these nutritional challenges.
The effectiveness of these strategies as adjunct treatments to OMMs remains unclear.

AI simplified

Several novel incretin-based obesity management medications (OMMs) have recently been approved for chronic weight management in adults with obesity or overweight. These agents have demonstrated substantial weight reduction effects alongside glucoregulatory and cardioprotective benefits. However, the use of incretin-based OMMs presents nutritional challenges that remain insufficiently addressed. These include side effects such as gastrointestinal disturbances and loss of lean body mass, which may compromise nutritional status, reduce energy expenditure, and heighten risk of rebound weight gain, sarcopenia, and frailty. Moreover, although these medications effectively suppress energy intake and reduce food quantity, they may also have unintended effects on diet quality, potentially influencing macronutrient distribution, ultraprocessed food consumption, risk of vitamin and mineral deficiencies, and disordered eating behaviors, which could undermine long-term weight maintenance and the cardiometabolic benefits achieved through these pharmacotherapy agents. Emerging evidence suggests that specific dietary and behavioral strategies, such as higher protein intake, resistance training, nutrient-dense eating patterns, and fostering adaptive eating behaviors, may help mitigate nutritional challenges and physiologic deterioration during significant weight reduction while also supporting cardiometabolic health maintenance. However, the application of these strategies as adjunct treatments alongside the new OMMs remains unclear. This narrative review summarizes the current literature on these issues and proposes dietary interventions and behavioral modification strategies aimed at mitigating the adverse effects that can be associated with incretin-based OMMs. These considerations are increasingly important given the expanding use of these medications, the degree of weight reduction they induce, and the implications for specific at-risk groups, including aging populations prone to muscle and functional decline and individuals with pre-existing conditions of nutritional deficiencies, chronic diseases, and disordered eating patterns.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (XML) ↗View full text ↗

Nutritional Challenges of Incretin-Based Obesity Management Medications: Implications for Clinical Practice

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief